BACKGROUND: Because classic pneumococcal serotyping methods cannot distinguish between serotypes 6A and 6C, the effects of pneumococcal vaccines against serotype 6C are unknown. Pneumococcal vaccines contain serotype 6B but not serotypes 6A and 6C. METHODS: We used a phagocytic killing assay to estimate the immunogenicity of the 7-valent conjugate vaccine (PCV7) in children and the 23-valent polysaccharide vaccine (PPV23) in adults against serotypes 6A and 6C. We evaluated trends in invasive pneumococcal disease (IPD) caused by serotypes 6A and 6C in the United States, using active surveillance. RESULTS: Serum specimens from PCV7-immunized children had median opsonization indices of 150 and < 20 for serotypes 6A and 6C, respectively. Similarly, only 52% of adults (25 of 48) vaccinated with PPV23 showed opsonic indices of > 20 against serotype 6C. During 1999--2006, the incidence of serotype 6A IPD decreased by 91% (from 4.9 to 0.46 cases per 100,000 persons; P < .05) among individuals aged < 5 years and by 58% (from 0.86 to 0.36 cases per 100,000 persons; P < .05) among those aged > or = 5 years. Although the incidence of 6C IPD showed no consistent trend (range, 0-0.6 cases per 100,000 persons) among individuals aged < 5 years, it increased from 0.25 to 0.62 cases per 100,000 persons (P < .05) among those aged > or = 5 years. CONCLUSIONS: PCV7 introduction has led to reductions in serotype 6A IPD but not serotype 6C IPD in the United States.
BACKGROUND: Because classic pneumococcal serotyping methods cannot distinguish between serotypes 6A and 6C, the effects of pneumococcal vaccines against serotype 6C are unknown. Pneumococcal vaccines contain serotype 6B but not serotypes 6A and 6C. METHODS: We used a phagocytic killing assay to estimate the immunogenicity of the 7-valent conjugate vaccine (PCV7) in children and the 23-valent polysaccharide vaccine (PPV23) in adults against serotypes 6A and 6C. We evaluated trends in invasive pneumococcal disease (IPD) caused by serotypes 6A and 6C in the United States, using active surveillance. RESULTS: Serum specimens from PCV7-immunized children had median opsonization indices of 150 and < 20 for serotypes 6A and 6C, respectively. Similarly, only 52% of adults (25 of 48) vaccinated with PPV23 showed opsonic indices of > 20 against serotype 6C. During 1999--2006, the incidence of serotype 6A IPD decreased by 91% (from 4.9 to 0.46 cases per 100,000 persons; P < .05) among individuals aged < 5 years and by 58% (from 0.86 to 0.36 cases per 100,000 persons; P < .05) among those aged > or = 5 years. Although the incidence of 6C IPD showed no consistent trend (range, 0-0.6 cases per 100,000 persons) among individuals aged < 5 years, it increased from 0.25 to 0.62 cases per 100,000 persons (P < .05) among those aged > or = 5 years. CONCLUSIONS:PCV7 introduction has led to reductions in serotype 6A IPD but not serotype 6C IPD in the United States.
Authors: Daniel A Scott; Steven F Komjathy; Branda T Hu; Sherryl Baker; Lois A Supan; Carol A Monahan; William Gruber; George R Siber; Stephen P Lockhart Journal: Vaccine Date: 2007-06-26 Impact factor: 3.641
Authors: Blanca E Gonzalez; Kristina G Hulten; Linda Lamberth; Sheldon L Kaplan; Edward O Mason Journal: Pediatr Infect Dis J Date: 2006-04 Impact factor: 2.129
Authors: Moe H Kyaw; Ruth Lynfield; William Schaffner; Allen S Craig; James Hadler; Arthur Reingold; Ann R Thomas; Lee H Harrison; Nancy M Bennett; Monica M Farley; Richard R Facklam; James H Jorgensen; John Besser; Elizabeth R Zell; Anne Schuchat; Cynthia G Whitney Journal: N Engl J Med Date: 2006-04-06 Impact factor: 91.245
Authors: Rekha Pai; Matthew R Moore; Tamara Pilishvili; Robert E Gertz; Cynthia G Whitney; Bernard Beall Journal: J Infect Dis Date: 2005-11-01 Impact factor: 5.226
Authors: Cynthia G Whitney; Monica M Farley; James Hadler; Lee H Harrison; Nancy M Bennett; Ruth Lynfield; Arthur Reingold; Paul R Cieslak; Tamara Pilishvili; Delois Jackson; Richard R Facklam; James H Jorgensen; Anne Schuchat Journal: N Engl J Med Date: 2003-05-01 Impact factor: 91.245
Authors: Lauri A Hicks; Lee H Harrison; Brendan Flannery; James L Hadler; William Schaffner; Allen S Craig; Delois Jackson; Ann Thomas; Bernard Beall; Ruth Lynfield; Arthur Reingold; Monica M Farley; Cynthia G Whitney Journal: J Infect Dis Date: 2007-10-04 Impact factor: 5.226
Authors: Catherine Satzke; Belinda D Ortika; Shahin Oftadeh; Fiona M Russell; Roy M Robins-Browne; E Kim Mulholland; Gwendolyn L Gilbert Journal: J Clin Microbiol Date: 2010-09-01 Impact factor: 5.948
Authors: J M Marimon; M Ercibengoa; M Alonso; G García-Medina; E Pérez-Trallero Journal: Eur J Clin Microbiol Infect Dis Date: 2010-05-14 Impact factor: 3.267
Authors: William P Hanage; Jonathan A Finkelstein; Susan S Huang; Stephen I Pelton; Abbie E Stevenson; Ken Kleinman; Virginia L Hinrichsen; Christophe Fraser Journal: Epidemics Date: 2010-06 Impact factor: 4.396
Authors: Alessia Melegaro; Yoon Hong Choi; Robert George; W John Edmunds; Elizabeth Miller; Nigel J Gay Journal: BMC Infect Dis Date: 2010-04-08 Impact factor: 3.090